153 related articles for article (PubMed ID: 19068457)
1. Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
Galán Brotons A; Borrás-Blasco J; Rosique-Robles JD; Vicent Verge JM; Casterá ME
Clin Transl Oncol; 2008 Dec; 10(12):844-6. PubMed ID: 19068457
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib-induced eruptive melanocytic lesions.
Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
[No Abstract] [Full Text] [Related]
5. Sorafenib TARGET trial results in Spanish patients.
Bellmunt J; González-Larriba JL; Climent MA; López-Vivanco G; Urruticoechea L; Albanell J
Clin Transl Oncol; 2007 Oct; 9(10):671-3. PubMed ID: 17974528
[TBL] [Abstract][Full Text] [Related]
6. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Hong DS; Reddy SB; Prieto VG; Wright JJ; Tannir NM; Cohen PR; Diwan AH; Evans HL; Kurzrock R
Arch Dermatol; 2008 Jun; 144(6):779-82. PubMed ID: 18559769
[TBL] [Abstract][Full Text] [Related]
7. [Sorafenib(Nexavar)].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
[TBL] [Abstract][Full Text] [Related]
8. [Sorafenib-induced multiple eruptive keratoacanthomas].
Jantzem H; Dupre-Goetghebeur D; Spindler P; Merrer J
Ann Dermatol Venereol; 2009 Dec; 136(12):894-7. PubMed ID: 20004316
[TBL] [Abstract][Full Text] [Related]
9. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
10. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
[TBL] [Abstract][Full Text] [Related]
11. Invasive squamous cell carcinoma and sorafenib in a black patient.
Donaldson MR; Stetson CL; Smith JL
Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
[No Abstract] [Full Text] [Related]
12. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
13. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Sibaud V; Delord JP; Chevreau C
Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
[TBL] [Abstract][Full Text] [Related]
14. Chloracne-like drug eruption associated with sorafenib.
Pickert A; Hughes M; Wells M
J Drugs Dermatol; 2011 Nov; 10(11):1331-4. PubMed ID: 22052319
[TBL] [Abstract][Full Text] [Related]
15. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
Staehler M; Haseke N; Schöppler G; Stadler T; Heinemann G; Stief CG
Urologe A; 2006 Oct; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
[TBL] [Abstract][Full Text] [Related]
16. Non-pigmenting fixed drug eruption induced by sorafenib.
Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K
Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
[No Abstract] [Full Text] [Related]
17. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Kodaira M; Takahashi S; Takeuchi K; Yuasa T; Saotome T; Yonese J; Fukui I; Hatake K
Ann Oncol; 2010 Jul; 21(7):1563-1565. PubMed ID: 20573851
[No Abstract] [Full Text] [Related]
19. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B
Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib-induced eruption resembling pityriasis rubra pilaris.
Paz C; Querfeld C; Shea CR
J Am Acad Dermatol; 2011 Aug; 65(2):452-453. PubMed ID: 21763585
[No Abstract] [Full Text] [Related]
[Next] [New Search]